Zacks Research Issues Negative Forecast for IQVIA Earnings

Key Points

• Zacks Research lowered its Q3 2025 EPS estimate for IQVIA to $2.64, down from $2.74, while the consensus estimate for full-year earnings is $10.84 per share.
• IQVIA's share price has been rated as a "Moderate Buy" with a consensus target price of $228.62 by various analysts, with notable upgrades from Barclays and Truist Financial.
• After reporting Q2 earnings of $2.81 EPS, exceeding expectations, the company's stock has shown strong annual revenue growth of 5.3% with a market cap of $32.21 billion.

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Stock analysts at Zacks Research decreased their Q3 2025 EPS estimates for shares of IQVIA in a research report issued to clients and investors on Tuesday, August 12th. Zacks Research analyst Team now expects that the medical research company will post earnings of $2.64 per share for the quarter, down from their previous forecast of $2.74. The consensus estimate for IQVIA's current full-year earnings is $10.84 per share. Zacks Research also issued estimates for IQVIA's Q4 2025 earnings at $3.05 EPS, FY2025 earnings at $10.59 EPS, Q2 2026 earnings at $2.74 EPS, Q4 2026 earnings at $3.14 EPS, FY2026 earnings at $11.55 EPS, Q2 2027 earnings at $3.32 EPS and FY2027 earnings at $13.00 EPS.

Several other equities research analysts have also recently issued reports on IQV. JPMorgan Chase & Co. lowered their price objective on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Robert W. Baird boosted their price target on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Evercore ISI boosted their price target on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. HSBC lowered shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the company from $260.00 to $160.00 in a report on Friday, April 25th. Finally, Mizuho lifted their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Trading Up 0.1%

IQVIA stock traded up $0.0970 during trading hours on Friday, hitting $192.6370. The company had a trading volume of 1,093,641 shares, compared to its average volume of 1,979,047. The firm has a market cap of $32.75 billion, a P/E ratio of 27.88, a P/E/G ratio of 2.10 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a 50-day moving average price of $171.16 and a two-hundred day moving average price of $168.34.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm's quarterly revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS.

Institutional Investors Weigh In On IQVIA

A number of large investors have recently modified their holdings of the business. Sowell Financial Services LLC purchased a new stake in shares of IQVIA in the first quarter valued at about $305,000. Mather Group LLC. grew its holdings in shares of IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after purchasing an additional 350 shares during the period. Private Advisor Group LLC grew its holdings in shares of IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after purchasing an additional 566 shares during the period. Park Avenue Securities LLC boosted its stake in IQVIA by 40.4% during the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company's stock worth $956,000 after buying an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company's stock worth $2,338,000 after purchasing an additional 3,398 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at $557,352.30. This represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.